RxSight Earnings Call: Strong Core, Cautious Outlook

Rxsight, Inc. ((RXST)) has held its Q4 earnings call. Read on for the main highlights of the call.

RxSight’s latest earnings call painted a mixed picture for investors, blending strong operational momentum in its core light adjustable lens business with tangible short‑term financial headwinds. Management stressed improving utilization, compelling clinical data and a cash‑rich balance sheet, but tempered optimism with conservative 2026 assumptions amid manufacturing and capital equipment challenges.

Core LAL Business Drives Record Mix and Margins

Light adjustable lens revenue reached $28.2 million in Q4 and represented a record 86% of total sales, up sharply from 71% a year earlier. Gross margin climbed to 77.5% in the quarter and 76.6% for 2025, underscoring the attractive economics of the LAL franchise even as other parts of the business softened.

Moderate Full-Year Growth Despite Product Mix Drag

For 2025, RxSight delivered 4% sales growth to $134.5 million, powered by a 12% increase in LAL sales. This expansion came despite a steep decline in LDD revenue, highlighting how the company’s consumables engine is increasingly offsetting weakness in capital placements.

Installed Base Expansion Sets Up Utilization Upside

The installed base of LDD systems grew 17% year over year to 1,134 units, creating a broader platform for recurring lens revenue. Management framed this footprint as a key lever for future growth, with a focus on driving same‑store utilization as commercial programs gain traction.

Clinical Data Underscore Competitive Moat

RxSight highlighted a post‑approval study showing 93% of lenses achieved both spherical equivalent and residual cylinder within 0.5 diopters of target. A registry covering more than 20,000 eyes further supported superior refractive accuracy, reinforcing the technology’s differentiation in real‑world practice.

Balance Sheet Strength Enables Continued Investment

The company ended 2025 with about $228 million in cash, cash equivalents and short‑term investments and carried no debt. This liquidity provides meaningful flexibility to fund R&D, commercial execution and measured international expansion without near‑term financing pressure.

Sequential Recovery Signals Operational Progress

LAL units in Q4 totaled 28,611, down 2% year over year but up 10% sequentially as procedure volumes improved. Management pointed to better utilization trends and encouraging early results from targeted field initiatives as evidence that the business is regaining momentum exiting the year.

Innovation Engine and Global Footprint Expand

Over the past five years, RxSight has secured roughly 20 FDA approvals and plans additional submissions over the next 18 months, keeping its pipeline active. The company also cited regulatory approvals in Europe, the U.K. and several Asia‑Pacific markets as laying groundwork for longer‑term international growth.

Sharp LDD Revenue Drop Weighs on Results

The light delivery device business was a clear weak spot, with Q4 units falling to 25 from 83 a year earlier, cutting quarterly LDD revenue to about $3 million from roughly $11 million. For the full year, LDD revenue declined 48%, creating a notable drag on overall top‑line performance.

Q4 Sales Contraction and Cautious Near-Term View

Quarterly sales fell 19% year over year to $32.6 million, underscoring the near‑term impact of lower LDD placements and inventory dynamics. Management’s 2026 outlook calls for a revenue decline at the midpoint and flags Q1 as the trough, signaling that investors should brace for a transition year.

GAAP Loss Widens as Investments Continue

Full‑year GAAP net loss increased to $38.9 million, or $0.95 per share, compared with a $27.5 million loss, or $0.71 per share, in 2024. The Q4 GAAP loss was $9.2 million, reflecting the cost of scaling the business and absorbing near‑term revenue and margin pressure.

Operating Costs and Equity Compensation Remain High

Total operating expenses rose 11% to $151.2 million in 2025, driven by added personnel and ongoing R&D and commercial spending. Stock‑based compensation was also meaningful at $7.8 million in Q4 and $31.6 million for the year, with a similar level embedded in the 2026 plan.

Manufacturing and Inventory Issues Pressure Margins

Management warned that higher‑cost inventory tied to lower 2025 production and absorption headwinds will weigh on profitability. As a result, 2026 gross margin is expected to drop to the 70%–72% range, down from 76.6% in 2025, though the company views these pressures as temporary.

International Upside to Build Slowly

Despite having approvals across multiple regions including the EU and Asia‑Pacific, RxSight anticipates only modest contributions from outside the U.S. next year. The strategy is to prioritize early capital placements and a disciplined rollout, suggesting that global revenue will ramp gradually rather than surge.

Conservative Volume Outlook Caps Near-Term Upside

For 2026, planning assumptions call for low single‑digit growth in LAL units and only a slight pickup in LDD placements, exiting at about 25 units per quarter. This implies utilization stabilizing around eight lenses per device per month, limiting near‑term leverage but potentially setting a conservative bar.

Guidance Signals Transition Year Before Recovery

RxSight guided 2026 revenue to $120 million–$135 million, roughly a 5% decline at the midpoint versus 2025, with a weak first quarter followed by improvement in the back half as comparisons ease. The company expects gross margins of 70%–72% and operating expenses between $150 million and $160 million, while relying on modest international sales, incremental LDD placements and a strong cash position to navigate this consolidation phase.

RxSight’s call outlined a company with a strong core product, a growing installed base and powerful clinical validation, yet also facing a reset year as LDD sales slump and manufacturing issues compress margins. Investors will be watching whether improving utilization, disciplined spending and international expansion can translate today’s operational strengths into a more robust growth and profit trajectory beyond 2026.